About

Dr. Yvonne Lin is an Assistant Dean for Academic Affairs and an Associate Professor in the Department of Pharmaceutics at the University of Washington School of Pharmacy. She holds a BA in Biophysics from the University of California at Berkeley and a PhD in Pharmaceutical Sciences from the University of Washington. Her research interests include natural product-drug interactions, regulation of drug metabolizing enzymes in children and pregnant women, and the use of metabolomics to discover endogenous biomarkers of drug metabolism and transport. Dr. Lin completed a postdoctoral fellowship at St. Jude Children’s Research Hospital. She is actively involved in teaching courses such as PHARBE 506, PHARBE 510, PCEUT 507, and PCEUT 537, and accepts students into her lab for research.

Research topics

• Internal medicine
• Biochemistry
• Medicine
• Urology
• Computational biology
• Bioinformatics
• Genetics
• Endocrinology
• Chemistry
• Environmental chemistry
• Organic chemistry
• Chromatography
• Pharmacology
• Biology

Selected publications

• Semi‐Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation

  CPT Pharmacometrics & Systems Pharmacology · 2026-02-22

  articleOpen access

  Paracetamol (PCM) is extensively metabolized in the liver via glucuronidation, sulfation, and oxidation. Although oral and intravenous PCM are commonly used interchangeably, a comprehensive evaluation of PCM metabolism across both routes is lacking. This study aimed to characterize the full pharmacokinetic (PK) profiles of PCM and its metabolites following oral and intravenous administration, accounting for presystemic and systemic metabolism. Concentrations of PCM, PCM-glucuronide (PCM-GLU), PCM-sulfate (PCM-SUL), PCM-cysteine (PCM-CYS), and PCM-mercapturate (PCM-MER) were pooled from three clinical studies, involving 53 adults with obesity and 16 adults without obesity (18-65 years, 53-198 kg). A semi-physiological population PK model was developed with nonlinear mixed-effects modeling, incorporating intestinal and liver compartments, and enterohepatic recirculation. A semi-physiological PK model incorporating presystemic and systemic hepatic metabolism captured PK of PCM and PCM-SUL following oral and intravenous administration. Intestinal oxidative metabolism for PCM-CYS and PCM-MER and enterohepatic recirculation for PCM-GLU were added to capture their full PK profiles. The estimated fraction of PCM absorbed was 0.745 (95% CI 0.699-0.792), with extensive first-pass metabolism and faster metabolite formation after oral than after intravenous administration. This semi-physiological population PK model identified both hepatic and intestinal presystemic metabolism of PCM, as well as enterohepatic recirculation of PCM-GLU. Oral administration of PCM results in faster metabolite formation than intravenous dosing, mainly for the oxidative metabolites. This modeling approach may support the quantification of presystemic and systemic metabolism, which can be relevant for oral and intravenous dosing of drugs metabolized by multiple pathways.

  PublisherDOI

• Impact of the gut microbiome on hepatic cytochrome P450 3A4 (CYP3A4) in humanized pregnane X receptor-constitutive androstane receptor-CYP3A4/3A7 mice

  Drug Metabolism and Disposition · 2026-03-26

  articleOpen accessSenior author

  ). A total of 57 bacterial species from the mouse gut microbiome were identified to be significantly correlated with CYP3A4 protein expression (P < .05). Five bile acids and no short-chain fatty acids were correlated with CYP3A4 protein expression. In summary, alterations in the gut microbiome influenced hepatic CYP3A4 in humanized mice in a sex-dependent manner, with distinct microbes strongly correlating with this regulatory pattern. SIGNIFICANCE STATEMENT: To the best of our knowledge, this study is the first to evaluate the expression of cytochrome P450 3A4 under different microbial conditions in a humanized mouse model, including conventionalization of germ-free mice using pooled sex-matched human feces. Alterations in the gut microbiome influenced hepatic cytochrome P450 3A4 in a sex-dependent manner and were strongly correlated with microbial species.

  PublisherDOI

• Metabolomics Approaches in Toxicology

  Elsevier eBooks · 2025-02-04

  book-chapter1st authorCorresponding
  PublisherDOI

• A Multidimensional Database for Biomonitoring of Quaternary Ammonium Compounds and Their Phase I Metabolites in Human Feces (Abstract ID: 161253)

  Journal of Pharmacology and Experimental Therapeutics · 2025-03-01

  articleOpen access
  PublisherOA PDFDOI

• The gut microbiome regulates hepatic drug processing genes in livers of humanized PXR-CAR-CYP3A4/3A7 mice

  Drug Metabolism and Pharmacokinetics · 2025-06-01

  articleSenior author
  PublisherDOI

• Development and Application of a Multidimensional Database for the Detection of Quaternary Ammonium Compounds and Their Phase I Hepatic Metabolites in Humans

  Environmental Science & Technology · 2024 · 21 citations

  • Chemistry
  • Chromatography
  • Environmental chemistry

  ), and MS/MS spectra for 19 parent QACs and 81 QAC metabolites. Using this database, we confidently identified 13 parent QACs and 35 metabolites in de-identified human fecal samples. This is the first study to integrate in vitro metabolite biosynthesis with LC-IM-MS/MS for the simultaneous monitoring of parent QACs and their metabolites in humans.

  PublisherOA PDFDOI

• Metabolism and pharmacokinetics of vitamin D in patients with cystic fibrosis

  The Journal of Steroid Biochemistry and Molecular Biology · 2023-05-20 · 5 citations

  articleOpen accessSenior author
  PublisherOA PDFDOI

• Editorial: Women in obstetric and pediatric pharmacology: 2021

  Frontiers in Pharmacology · 2023-04-12

  editorialOpen accessSenior author

  EDITORIAL article Front. Pharmacol., 12 April 2023Sec. Obstetric and Pediatric Pharmacology Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1191285

  PublisherOA PDFDOI

• The plasma free fraction of 25-hydroxyvitamin D3 is not strongly associated with 25-hydroxyvitamin D3 clearance in kidney disease patients and controls

  The Journal of Steroid Biochemistry and Molecular Biology · 2022-10-28 · 3 citations

  articleOpen access
  PublisherOA PDFDOI

• Pharmacokinetics of 38 Percent Silver Diamine Fluoride in Children.

  PubMed · 2022-03-15 · 9 citations

  articleOpen access

  PURPOSE: The purpose of this study was to measure serum levels and characterize the pharmacokinetics of silver and fluoride in healthy children receiving silver diamine fluoride (SDF) treatment for dental caries lesions. METHODS: Children (three to 13 years old with at least one caries lesion) were recruited at the University of California, San Francisco Pediatric Dental Clinic from August 2019 through March 2020. Blood was obtained at one randomly selected timepoint up to 168 hours after SDF application. Serum fluoride and silver were measured, and population pharmacokinetic modeling was used to estimate pharmacokinetic parameters and simulate silver concentration versus time profiles in cohorts of children (15 to 50 kg). RESULTS: Fifty-five children completed the study. Serum fluoride had no discernable temporal pattern. Silver concentra- tions were best described by a one-compartment model with first-order absorption and elimination, and weight as a covariate. Simulated 15 kg children had higher predicted peak silver concentrations than simulated 50 kg children (22.0 ng/mL [95 percent confidence interval {95 percent CI} equals 19.4 to 24.6] versus 12.8 ng/mL [95 percent CI equals 11.3 to 14.3]), and a longer predicted silver half-life (15.5 days [95 percent CI equals 12.5 to 18.5] versus 4.0 days [95 percent CI equals 2.7 to 5.3]). CONCLUSIONS: Evidence presented indicate that topical silver diamine fluoride application in children is safe, and serum concentrations of fluoride and silver pose little risk of toxicity.

  PublisherOA PDF

Recent grants

• NIH Grant R01HD058556

  NIH · $2.7M · 2016

• Building Research across Interdisciplinary Gaps (BRIDG) T90/R90 Training Program

  NIH · $3.9M · 2015–2025

Frequent coauthors

• Kenneth E. Thummel

  University of Washington

  43 shared

• Erin G. Schuetz

  28 shared

• Mary F. Paine

  Washington State University Spokane

  25 shared

• Scott J. Brantley

  16 shared

• Swati Nagar

  Temple University

  16 shared

• Aneesh A. Argikar

  Syneos Health (United States)

  16 shared

• Jatinder K. Lamba

  Florida College

  15 shared

• Danny D. Shen

  University of Washington

  15 shared

Education

• B.A., Biophysics

  University of California at Berkeley

• Ph.D., Pharmaceutical Sciences

  University of Washington